Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood
Sponsor: Accelerate Diagnostics, Inc.
A observational or N/A phase clinical study on Bacteremia and Enterobacteriaceae Infections, this trial is completed. The trial is conducted by Accelerate Diagnostics, Inc. and has accumulated 10 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Apr 2022 — Jul 2024 [monthly]
Completed
Status: Enrolling By Invitation → Completed
-
Mar 2021 — Apr 2022 [monthly]
Enrolling By Invitation
-
Jan 2021 — Mar 2021 [monthly]
Enrolling By Invitation
▶ Show 5 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Enrolling By Invitation
-
Sep 2018 — Dec 2019 [monthly]
Enrolling By Invitation
-
Jun 2018 — Sep 2018 [monthly]
Enrolling By Invitation
-
Apr 2018 — Jun 2018 [monthly]
Enrolling By Invitation
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Enrolling By Invitation NA
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Accelerate Diagnostics, Inc.
- Denver Health and Hospital Authority
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .